SEHK:1177Pharmaceuticals
Breakthrough Hepatitis B Drug TQA3605 Might Change The Case For Investing In Sino Biopharmaceutical (SEHK:1177)
Sino Biopharmaceutical recently reported that its independently developed Class I innovative drug TQA3605, a core protein allosteric modulator, met the primary endpoint in a randomized, double-blind, placebo-controlled Phase II trial in chronic hepatitis B patients on nucleos(t)ide analogues, significantly improving viral suppression with a generally favorable safety profile.
Because no core protein allosteric modulator for hepatitis B is yet approved globally and diagnosis and treatment...